Company Overview of Saladax Biomedical, Inc.
Saladax Biomedical, Inc. develops and commercializes diagnostic blood tests for the delivery of personalized medicine in oncology. The company provides MyCare chemotherapy exposure optimization tests, such as My5-FU, a chemotherapy used in the treatment of colorectal, breast, and head and neck cancers; MyPaclitaxel, a chemotherapy used in the treatment of breast, non-small cell lung, ovarian, and digestive tract cancers; and MyDocetaxel, a chemotherapy used in the treatment of breast cancer, as well as non-small cell lung, digestive tract, prostate, and head and neck cancers. It markets and sells its products through distributors in the United States and internationally. The company was foun...
116 Research Drive
Bethlehem, PA 18015
Founded in 2004
Key Executives for Saladax Biomedical, Inc.
Chairman, Chief Executive Officer and President
Founder, Chief Scientific Officer, Senior Vice President and Director
Founder, Chief Marketing Officer, Senior Vice President and Director
Vice President of Finance and Controller
Vice President of R&D and Operations
Compensation as of Fiscal Year 2014.
Saladax Biomedical, Inc. Key Developments
Saladax Biomedical, Inc. Announces U.S. Launch of MyImatinib Chemotherapy Exposure Optimization Test
Dec 1 14
Saladax Biomedical, Inc. announced the commercial launch of the MyImatinib(TM) test. MyImatinib is part of the Saladax line of MyCare(TM) diagnostic tests that determine a patient's exposure to chemotherapy in an effort to improve and personalize dosing. The MyCare tests are simple blood tests that provide oncologists with specific information about each patient's exposure to chemotherapy, helping the doctor to make informed decisions on drug dose adjustments, with the goals of maximizing the therapy's effectiveness and limiting its potential side effects. The MyImatinib tests will be managed through the Saladax Biomedical Laboratories (SBL), the CLIA-certified division of Saladax Biomedical. Imatinib is used in the treatment of multiple cancers, and is marketed in the United States by Novartis as Gleevec(R). MyImatinib joins the Saladax portfolio of tests that currently include My5-FU(TM), MyPaclitaxel(TM) and MyDocetaxel(TM). The MyCare tests are designed to provide oncologists with accurate, convenient and reliable information regarding Imatinib exposure levels.
GE Capital Increases Existing Credit Facility for Saladax Biomedical, Inc
Jul 22 13
GE Capital, Healthcare Financial Services announced that it has amended its existing $2 million senior secured credit facility to Saladax Biomedical, Inc. to provide an additional $8 million multi-draw term loan facility and to modify the terms of the existing $2 million term loan. GE Capital, Healthcare Financial Services is acting as administrative agent and sole lender for the credit facility. The loans will be used to provide Saladax with working capital to support ongoing commercialization efforts and for other corporate purposes.
Saladax Biomedical, Inc. Appoints John McAuliffe as Vice President of Companion Diagnostics Business Development
Jul 22 13
Saladax Biomedical, Inc. announced the hiring of John McAuliffe as Vice President of Companion Diagnostics Business Development. Mr. McAuliffe has over 20 years’ experience in healthcare serving in roles including drug development, sales, marketing and business development. Prior to joining Saladax, Mr. McAuliffe contributed to the success of Athena Diagnostics during his 13 year tenure by serving in various roles up to and including Director of Business Development, Neurology where he was responsible for management of biomedical research as well as the identification, evaluation and launch of over 100 protein and molecular diagnostic assays, which led to acquisition by Quest Diagnostics from Thermo Fisher Scientific in 2011.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|